Olafur Gisli Jonsson
Overview
Explore the profile of Olafur Gisli Jonsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taalas T, Oskarsson T, Heyman M, Lund B, Lepik K, Vaitkeviciene G, et al.
Haematologica
. 2025 Feb;
PMID: 39973352
Age and sex have historically been associated with differences in acute lymphoblastic leukemia (ALL) survival. In the NOPHO ALL2008 trial, patients aged 1-45 years with BCR::ABL1-negative B-precursor and Tcell ALL...
2.
Dam M, Centanni M, Friberg L, Centanni D, Karlsson M, Stensig Lynggaard L, et al.
Leukemia
. 2024 Jan;
38(4):712-719.
PMID: 38287133
Asparaginase is an essential component of acute lymphoblastic leukemia (ALL) therapy, yet its associated toxicities often lead to treatment discontinuation, increasing the risk of relapse. Hypersensitivity reactions include clinical allergies,...
3.
Oskarsson Y, Thors V, Vias R, Ludviksson B, Brynjolfsson S, Gianchecchi E, et al.
Acta Paediatr
. 2023 Dec;
113(3):606-614.
PMID: 38140806
Aim: The survival rate after treatment for childhood leukaemia has greatly improved, but could result in protracted immune deficiency. This study examined the immune status of children after chemotherapy and...
4.
Arad-Cohen N, Zeller B, Abrahamsson J, Navarro J, Cheuk D, Palmu S, et al.
Expert Rev Anticancer Ther
. 2022 Oct;
22(11):1183-1196.
PMID: 36191604
Introduction: Pediatric acute myeloid leukemia (AML) is the second most common type of pediatric leukemia. Patients with AML are at high risk for several complications such as infections, typhlitis, and...
5.
Karlsson L, Nyvold C, Soboli A, Johansson P, Palmqvist L, Tierens A, et al.
Int J Lab Hematol
. 2022 Aug;
44(6):1094-1101.
PMID: 35918824
Introduction: Analysis of measurable residual disease (MRD) is increasingly being implemented in the clinical care of children and adults with acute myeloid leukaemia (AML). However, MRD methodologies differ and discordances...
6.
Anastasopoulou S, Nielsen R, Als-Nielsen B, Banerjee J, Eriksson M, Helenius M, et al.
Haematologica
. 2022 Mar;
107(10):2318-2328.
PMID: 35354251
Central nervous system (CNS) toxicity is common at diagnosis and during treatment of pediatric acute lymphoblastic leukemia (ALL). We studied CNS toxicity in 1,464 children aged 1.0-17.9 years, diagnosed with...
7.
Helenius M, Vaitkeviciene G, Abrahamsson J, Jonsson O, Lund B, Harila-Saari A, et al.
Pediatr Blood Cancer
. 2022 Mar;
69(6):e29582.
PMID: 35316565
Background: White blood cell count (WBC) as a measure of extramedullary leukemic cell survival is a well-known prognostic factor in acute lymphoblastic leukemia (ALL), but its biology, including impact of...
8.
Jensen K, Oskarsson T, Lahteenmaki P, Flaegstad T, Jonsson O, Svenberg P, et al.
Leukemia
. 2022 Mar;
36(5):1274-1282.
PMID: 35314777
Relapse remains the main obstacle to curing childhood acute lymphoblastic leukemia (ALL). The aims of this study were to compare incidence of relapse, prognostic factors, and survival after relapse between...
9.
Egnell C, Heyman M, Jonsson O, Raja R, Niinimaki R, Albertsen B, et al.
Br J Haematol
. 2021 Nov;
196(5):1239-1247.
PMID: 34726257
Obesity is associated with poor outcomes in childhood acute lymphoblastic leukaemia (ALL). We explored whether severe treatment-related toxicity and treatment delays could explain this observation. This study included 1 443...
10.
Andres-Jensen L, Grell K, Rank C, Albertsen B, Tuckuviene R, Nielsen R, et al.
Leukemia
. 2021 Aug;
36(2):361-369.
PMID: 34389803
Endothelial dysfunction has not previously been investigated as a thrombogenic risk factor among patients with acute lymphoblastic leukemia (ALL), known to be at high risk of thromboembolism. We retrospectively explored...